- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
SAB Biotherapeutics Inc (SABS)
SAB Biotherapeutics Inc stock price live, this page displays NASDAQ SABS stock exchange data. View the SABS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the SAB Biotherapeutics Inc real time stock price chart below.
What Is the SAB Biotherapeutics Inc Stock Price Today?
The SAB Biotherapeutics Inc stock price today is 3.750.
What Is the Stock Symbol for SAB Biotherapeutics Inc?
The stock symbol for SAB Biotherapeutics Inc is "SABS."
What Stock Exchange Does SAB Biotherapeutics Inc Trade On?
SAB Biotherapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is SAB Biotherapeutics Inc a Good Stock to Buy?
Determining whether SAB Biotherapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SABS quote. (ISIN: US78397T2024)
What Is the SAB Biotherapeutics Inc Stock Price Today?
The SAB Biotherapeutics Inc stock price today is 3.750.
What Is the Stock Symbol for SAB Biotherapeutics Inc?
The stock symbol for SAB Biotherapeutics Inc is "SABS."
What Stock Exchange Does SAB Biotherapeutics Inc Trade On?
SAB Biotherapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is SAB Biotherapeutics Inc a Good Stock to Buy?
Determining whether SAB Biotherapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SABS quote. (ISIN: US78397T2024)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.600
3.770
52 wk Range
1.850
5.150
SABS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.6003.770
52 wk Range
1.8505.150
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SABS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
11.636
Upside
+210.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Form 8K SAB Biotherapeutics Inc For: 18 June- Investing.com
Form 4 SAB Biotherapeutics Inc For: 26 June- Investing.com
- Form 4 SAB Biotherapeutics Inc For: 26 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 11.636
(+210.30% Upside)
SAB Biotherapeutics Inc Earnings Call Summary for Q2/2026
- SAB Bio reported Q2 2026 net loss of $22.5M vs. $10.1M year-ago; R&D spending more than doubled to $16.2M as SAFEGUARD trial advanced.
- Company holds $208M in cash and investments, sufficient to fund operations through 2028; stock rose 4.46% in premarket to $3.938.
- Over 60 sites recruiting for SAFEGUARD Phase II-B trial; enrollment expected to complete Q4 2026 with top-line data due second half 2027.
- PRISE-hATG trial enrollment to begin H2 2026 for patients beyond 100-day diagnosis window; results expected Q1 2029.
- Management cited Tzield's Stage 3 approval as validation for regulatory pathway; positioned SAB-142 as competitor with two-day vs. 12-day dosing.
Last Updated: 2026-08-06, 09:18 a/m
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.28 / -0.27
Revenue / Forecast
-- / --
Compare SABS to Peers and Sector
Metrics to compare | SABS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSABSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −15.7x | −5.0x | −0.4x | |
PEG Ratio | −0.25 | 0.07 | 0.00 | |
Price/Book | 1.6x | 3.1x | 2.6x | |
Price / LTM Sales | - | 4.4x | 3.1x | |
Upside (Analyst Target) | 224.3% | 100.4% | 49.0% | |
Fair Value Upside | Unlock | 20.4% | 7.1% | Unlock |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the SAB Biotherapeutics (SABS) Stock Price Today?
The SAB Biotherapeutics stock price today is 3.750 USD.
What Stock Exchange Does SAB Biotherapeutics Trade On?
SAB Biotherapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for SAB Biotherapeutics?
The stock symbol for SAB Biotherapeutics is "SABS."
What Is the SAB Biotherapeutics Market Cap?
As of today, SAB Biotherapeutics market cap is 342.110M USD.
What Is SAB Biotherapeutics's Earnings Per Share (TTM)?
The SAB Biotherapeutics EPS (TTM) is -1.556.
When Is the Next SAB Biotherapeutics Earnings Date?
SAB Biotherapeutics will release its next earnings report on Nov 17, 2026.
From a Technical Analysis Perspective, Is SABS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has SAB Biotherapeutics Stock Split?
SAB Biotherapeutics has split 1 times.
How Many Employees Does SAB Biotherapeutics Have?
SAB Biotherapeutics has 86 employees.
What is the current trading status of SAB Biotherapeutics (SABS)?
As of Sep 03, 2026, SAB Biotherapeutics (SABS) is trading at a price of 3.750 USD, with a previous close of 3.750 USD. The stock has fluctuated within a day range of 3.600 USD to 3.770 USD, while its 52-week range spans from 1.850 USD to 5.150 USD.
What Is SAB Biotherapeutics (SABS) Price Target According to Analysts?
The average 12-month price target for SAB Biotherapeutics is 11.636 USD, with a high estimate of 16 USD and a low estimate of 6 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +210.30% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.